Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...
News-Medical.Net on MSN
Blocking key protein restores healthy lung function and reduces fibrosis in mice
Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...
The Chosun Ilbo on MSN
Jascayd Approved: First New Pulmonary Fibrosis Drug in a Decade
A new drug to alleviate idiopathic pulmonary fibrosis, a condition where the lungs harden and make breathing difficult, has ...
Tivardi Therapeutics shares plunge after phase 2 trial setbacks for TTI-101 in pulmonary fibrosis. Read more here.
Idiopathic pulmonary fibrosis is a potentially fatal disease currently without treatment, in which lung tissue develops scarring and becomes stiff, making breathing increasingly difficult over time.
Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF.
In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.
Devan Boutin, Cardiac Rehabilitation Supervisor at UHS Chenango Memorial, demonstrates the equipment he uses to help patients breathe easier, move better, and live more fully as they recover from a ...
The Norwegian palace has confirmed that Crown Princess Mette-Marit will be absent from royal duties for a month as she enters "pulmonary rehabilitation" amid her ongoing battle with pulmonary fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback